#United States #San Jose #Lung Cancer #LEADOPTIK #LIA™ System

LEADOPTIK Completes First-in-Human Use of LIA™ System

LEADOPTIK, a pioneering medical technology firm, recently took a monumental step in the field of lung cancer diagnostics by successfully completing the first-ever human use of its Last Inch Assessment™ (LIA) system. This significant achievement was performed at the prestigious University of Chicago Medical Center, following the system's clearance from the U.S. Food and Drug Administration (FDA).

The LIA™ system is designed to enhance precision during lung biopsy procedures by providing real-time insights at crucial points of tissue sampling. The recent FDA clearance symbolizes not merely an operational victory but also a promising new chapter in the fight against lung cancer, which remains the leading cause of cancer-related fatalities globally.

During the groundbreaking first-in-human case, the integrated optical imaging technology of the LIA™ system offered depth-resolved information that enabled physicians to validate the accuracy of collected biopsy samples effectively. Dr. D. Kyle Hogarth, a leading figure in the field of interventional pulmonology at the University of Chicago, noted the system's seamless integration into clinical processes, enhancing confidence at the biopsy stage. “The initial accuracy observed reinforced the confidence necessary for effective tissue sampling,” he stated, highlighting the system's transformative potential for clinicians and patients.

Reza Khorasaninejad, the CEO and Co-Founder of LEADOPTIK, expressed his enthusiasm about this milestone, reflecting on the years of painstaking development that led to this moment. He said, “After years of development and encouraging preclinical data, this milestone bridges a critical gap in diagnostic procedures, assisting clinicians in making informed decisions rapidly.” This innovative technology allows for real-time differentiation between nodules and healthy tissue, a feat previously deemed unattainable during biopsies.

Further insight was provided by Dr. Alex Chee, LEADOPTIK’s Chief Medical Officer, who recognized the natural fit of real-time tissue confirmation in ongoing biopsy workflows. He stated that the insights gained from these early human encounters would directly influence upcoming clinical studies and the subsequent evolution of their advanced software and AI capabilities.

Nick Byron, the Head of Business Development at LEADOPTIK, reinforced the significance of the inaugural treatment, expressing aspirations for broader adoption. He stated,